Multiple Myeloma

>

Latest News

UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications
UK’s MHRA Approves Belantamab Mafodotin/Chemo in Myeloma Indications

April 18th 2025

Results from the DREAMM-7 and DREAMM-8 trials support the approval of belantamab mafodotin with chemotherapy in relapsed/refractory multiple myeloma.

Data from the phase 3 CEPHEUS trial support the European Commission’s approval of the daratumumab-based regimen.
Daratumumab Combo Earns EU Approval in Newly Diagnosed Multiple Myeloma

April 16th 2025

Isa-VRd Shows Efficacy and Safety in Frail Transplant-Ineligible Myeloma
Isa-VRd Shows Efficacy and Safety in Frail Transplant-Ineligible Myeloma

April 13th 2025

Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM
Once-Weekly Doses of Carfilzomib Show Balanced Benefit in Real-World RRMM

April 7th 2025

Cytokine release syndrome events primarily occurred during step-up and the first full dosing cycle in patients with relapsed/refractory multiple myeloma.
Talquetamab Elicits Sustained Responses in Pre-Treated R/R Multiple Myeloma

April 1st 2025

Video Series
Video Interviews
Podcasts
Samantha Shenoy, NP, MSN, discusses how her role plays a vital part in patient care for those receiving talquetamab for multiple myeloma.
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.
Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.
Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.
Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.
Paul G. Richardson, MD, and Christina Gasparetto, MD, offer insights into the use of proteasome inhibitors in relapsed or refractory multiple myeloma.

More News